Eyelash Growth (Bimatoprost/Latisse) Treatment Guide

What most patients don't realize is that the discovery of Latisse was an accident. Bimatoprost was originally developed as an eye drop for glaucoma — to lower intraocular pressure. Clinicians started noticing, as an unexpected side effect, that patients' eyelashes were growing longer, thicker, and darker. Allergan recognized this and developed a separate product specifically for eyelash application. The FDA approved it in 2008, and Latisse became the first — and still the only — prescription treatment cleared for eyelash hypotrichosis.^[1]

I bring this up because it matters for understanding how this drug works, why it is effective, and why it carries the particular side effect profile it does. Bimatoprost does not coat lashes or add to them cosmetically. It changes the biology of your hair follicles. That distinction explains everything from why it takes months to see the full effect to why you lose the results when you stop.

This guide covers what I explain to patients considering bimatoprost: the mechanism, what the clinical trials actually showed, how to apply it correctly to minimize side effects, what OTC alternatives can and cannot do, and who is a good candidate for telehealth prescribing.

The Eyelash Hair Cycle: Why It Matters

To understand how bimatoprost works, you need a working knowledge of how eyelashes grow. Unlike the hair on your scalp, which goes through a multi-year growth cycle, eyelashes cycle much more rapidly — and for most of us, a relatively small percentage of lashes are actively growing at any given time.

The Three Phases

Anagen (Growth Phase): This is the active growth period. During anagen, the hair follicle is connected to its blood supply and the lash grows steadily. For eyelashes, anagen lasts approximately 30–45 days — far shorter than the 2–6 years that scalp hair spends growing.^[3] At any given moment, roughly 35–40% of your upper lashes are in this phase.

Catagen (Transition Phase): Growth slows and the follicle begins to shrink and detach from its blood supply. This phase lasts about 2–3 weeks. If a lash falls out during catagen, no new lash will grow from that follicle until catagen ends.

Telogen (Resting Phase): The follicle is dormant. The fully grown lash sits in the follicle until it naturally sheds and the cycle restarts. Telogen can last up to 100 days.^[3] The relatively long telogen phase explains why the total eyelash growth cycle — from one anagen to the next — averages 4–8 months.

This biology is directly relevant to bimatoprost's mechanism. The drug does not simply stimulate more follicles to grow — it prolongs how long they stay in the growth phase. It also increases follicle size, which accounts for the increase in lash thickness, and stimulates melanogenesis, making lashes appear darker.^[2]

How Bimatoprost Works: The Mechanism

Bimatoprost is a synthetic prostamide analogue — chemically similar to prostaglandin F2α (PGF2α), the same class of compounds that regulate fluid drainage in the eye (hence its original use in glaucoma). Prostaglandin receptors are present in the dermal papilla and outer root sheath of hair follicles, which is why these drugs affect lash growth at all.^[4]

When applied to the upper eyelid margin, bimatoprost acts on prostaglandin receptors in the follicle to produce three effects:

• Anagen phase prolongation: More follicles are in the active growth phase at any given time, and each anagen cycle lasts longer. This is the primary mechanism behind increased lash length.
• Follicle enlargement: The dermal papilla — the structure at the base of the follicle that determines hair caliber — increases in size. The hair bulb also enlarges. Together, these changes produce thicker, fuller lashes.^[2]
• Melanogenesis stimulation: Bimatoprost increases melanin production in the follicle, resulting in darker lashes. This is the same mechanism responsible for the iris pigmentation risk discussed in the side effects section.

What I tell patients is this: bimatoprost isn't a cosmetic product you apply on top of your lashes. It works at the level of the follicle, altering the biology of the growth cycle. That's why it takes months to see the full effect and why the results reverse when you stop — the follicles return to their natural cycling patterns once the drug is discontinued.

FDA Approval and Clinical Trial Evidence

The FDA approved bimatoprost 0.03% (Latisse) for eyelash hypotrichosis in 2008 under NDA #022231. This was based on randomized, double-masked, vehicle-controlled clinical trials conducted in adults with inadequate eyelashes.^[1]

What the Trials Showed

The foundational phase III trial and subsequent pooled analyses across six studies (n=680 in the bimatoprost group) demonstrated statistically significant improvements in all three primary endpoints at 16 weeks:^[1]

The Global Eyelash Assessment is a 4-point investigator-graded scale (1=minimal to 4=very marked prominence). Achieving at least a 1-grade improvement from baseline — accomplished by roughly 78% of bimatoprost users compared to 18% with placebo — was the primary efficacy endpoint.^[5]

In a proof-of-concept study cited in the FDA clinical review, 81% of subjects rated their overall eyelash appearance as "much improved" at 3 months, with 19% rating it "improved" — a 100% subjective improvement rate among completers.^[6]

The Discontinuation Effect

The 12-month phase 3 study included a design that allowed researchers to observe what happens when treatment stops. During the second six months, patients who had been on bimatoprost were switched to vehicle (placebo). Their lash improvements gradually reversed toward baseline. This confirms what the mechanism predicts: the drug's effects are dependent on ongoing application.^[1]

How to Apply Bimatoprost Correctly

Correct application is both how you get results and how you minimize side effects. The most common mistakes — applying to the lower lash line, using too much solution, or skipping the blotting step — are responsible for most of the side effects patients experience.

Step-by-Step Application

1. Remove makeup and contact lenses. Apply to a clean face. Contacts can absorb the solution; wait at least 15 minutes before reinserting.
2. Use a single-use applicator. Latisse comes with sterile, single-use applicator brushes. Use a new one for each eye — never reuse applicators. This is not optional; reusing applicators raises infection risk.
3. Place one drop on the applicator. One drop is sufficient. More is not more effective and increases side effect risk.
4. Draw the applicator along the upper eyelid margin — the skin at the very base of your upper lashes, from the inner corner to the outer corner. Think of it like applying an eyeliner stroke, directly where the lash meets the eyelid skin.
5. Do not apply to the lower lash line. The lower lashes are naturally shorter and the skin there is more prone to pigmentation changes. Bimatoprost is FDA-approved for upper lash application only.
6. Blot any excess immediately. Use a clean tissue to dab away any solution that drips or spreads beyond the lash line. Excess solution on the periorbital skin is the primary driver of skin darkening.
7. Apply at night, once daily. Evening application is standard. Wash hands after handling the solution.

What to Expect: Treatment Timeline

Managing expectations is one of the most useful things I do when prescribing bimatoprost. Patients who understand the timeline stick with treatment long enough to see real results. Those who don't often quit at 6 weeks when they're "not seeing anything dramatic yet."

The 16-week timeline surprises many patients who expect something faster. Eyelash hypotrichosis responds to bimatoprost on the timeline dictated by the hair growth cycle — you cannot speed it up by applying more. Consistency matters far more than quantity.

Side Effects: What the Evidence Shows

The side effect profile of bimatoprost applied topically to the lash line is substantially more favorable than when the same drug is used as an eye drop for glaucoma. The difference is exposure: a glaucoma patient instills bimatoprost directly into the eye daily, saturating ocular tissue. A patient using Latisse for lashes is applying a small amount to skin at the lash margin, with very limited drug reaching the ocular surface.

Common Side Effects (Occur in More Than 1% of Patients)

Iris Color Change: The Risk That Gets the Most Attention

Increased iris pigmentation — gradual darkening of the iris, usually in patients with mixed-color or light brown eyes — is the side effect that generates the most patient concern. The risk is real and can be permanent. However, context matters here.

Iris darkening occurs primarily when bimatoprost is instilled directly into the eye (as with glaucoma drops) and accumulates in the iris stroma over time. When applied correctly to the upper lash margin — with blotting to remove excess, and never dropped into the eye — the amount of drug reaching the iris is very small. The published clinical trials of Latisse for eyelash hypotrichosis reported only 2 mild cases of iris hyperpigmentation among 680 treated subjects in the pooled safety analysis.^[1]

Who is at higher risk? Patients with hazel, light brown, blue, or green eyes where pigment distribution in the iris is uneven are more susceptible. Patients with dark brown irises have essentially no room for further darkening. If you have light eyes and are concerned, this is an important discussion to have with your prescribing physician before starting.

Periorbital Hyperpigmentation vs. Iris Darkening

These are two separate phenomena that patients often conflate. Periorbital hyperpigmentation means darkening of the skin around the eye — the eyelid skin near the application site. This is a result of bimatoprost's melanogenesis-stimulating effect on skin melanocytes. It is usually reversible when treatment is stopped, though in patients with darker baseline skin tones, it may take several months to fade. Iris darkening is a change to the color of the iris itself — the colored part of the eye — and occurs through a different mechanism (accumulation of melanin in iris stromal melanocytes). Iris darkening may be permanent.

Enophthalmos and Periorbital Changes

Long-term glaucoma patients on prostaglandin analogs sometimes develop a sunken appearance to the eye (enophthalmos) and orbital fat loss — a phenomenon called prostaglandin-associated periorbitopathy (PAP). This is most pronounced with bilateral, long-term ophthalmic use. Only one case of enophthalmos was reported in the 680-patient Latisse safety pooled analysis, and the risk appears substantially lower with the lash-application method than with glaucoma drops.^[1] Patients should be aware this is listed as a postmarketing observation and should report any noticeable change in orbital appearance to their physician.

Who Should Not Use Bimatoprost

The formal contraindication is hypersensitivity to bimatoprost or any component of the formulation. Beyond that, a prescribing physician will also evaluate several relative contraindications and cautions:

• Active intraocular inflammation (uveitis): Prostaglandin analogs can worsen uveitis and are avoided in active intraocular inflammation.
• Concurrent use of prostaglandin glaucoma drops (latanoprost, travoprost, tafluprost): Using two prostaglandin-class drugs simultaneously may paradoxically reduce the IOP-lowering effect of the glaucoma medication and increases overall prostaglandin exposure. Patients already using glaucoma drops should consult their ophthalmologist before starting Latisse.
• Aphakia or pseudophakia with torn posterior lens capsule: Prostaglandins increase the risk of macular edema in these patients.
• Pregnancy and breastfeeding: Systemic bimatoprost has shown adverse fetal effects in animal studies at doses far above human topical exposure. There are no adequate human studies. Given the elective nature of eyelash treatment, bimatoprost should not be used during pregnancy or while breastfeeding.
• Eyelid eczema or active dermatitis: Application to inflamed eyelid skin can worsen symptoms and alter drug absorption.

Bimatoprost vs. Latanoprost for Eyelash Growth

Latanoprost (Xalatan) is a prostaglandin F2α analogue used for glaucoma. Like bimatoprost, it was noted to cause eyelash growth as a side effect during its development for IOP-lowering. Latanoprost is sometimes used off-label for eyelash growth, but several head-to-head studies establish that bimatoprost is the stronger option for this specific purpose.

A six-month randomized clinical trial by Noecker and colleagues compared bimatoprost and latanoprost head-to-head. Eyelash growth was reported in 14 of 133 patients in the bimatoprost group, versus zero in the latanoprost group.^[3] Other studies by Eisenberg et al. and Tosti et al. found similar results and noted that hypertrichosis appears earlier with bimatoprost than with latanoprost. Latanoprost does produce some eyelash lengthening — one quantitative study measured a 0.8 mm increase in lash length after 10 weeks — but the effect is less consistent and the evidence base is smaller.

The practical takeaway: if a patient specifically wants eyelash enhancement, bimatoprost is the evidence-backed, FDA-approved choice. Latanoprost is not the right prescription for this indication.

OTC Alternatives: Separating Evidence from Marketing

Patients frequently ask about over-the-counter eyelash serums and growth products before considering a prescription. The honest answer is that no OTC product has clinical trial data demonstrating true eyelash growth. Here is what the evidence shows for the most commonly discussed options:

Castor Oil

Castor oil is probably the most widely promoted OTC option for lash growth, and it has no clinical trial evidence supporting the claim. What castor oil does well is coat and condition existing lashes. Its thick consistency forms a barrier that reduces mechanical breakage, and its main fatty acid (ricinoleic acid) may have some anti-inflammatory and moisturizing properties. The result is that lashes may look fuller or glossier over time — not because new growth has occurred, but because existing lashes are better protected.^[7]

One randomized trial did find that topical castor oil improved several measures of eyelid health in patients with blepharitis — including reducing eyelash crusting and madarosis — but this study was about eyelid disease management, not lash growth induction.^[8]

To actually lengthen eyelashes, a product needs to extend the anagen phase. Castor oil does not do this. If someone shows you before-and-after photos attributed to castor oil, the growth you're seeing is almost certainly the lash cycle running its natural course, better preserved lash condition from reduced breakage, or a change in how the lashes are photographed.

OTC "Lash Serums" and Peptide Products

The shelves — and social media — are full of OTC serums claiming to grow lashes. Most contain a combination of peptides, panthenol, biotin, and plant extracts. No product in this category has gone through randomized controlled trial testing with an FDA-regulated efficacy endpoint. Some contain prostaglandin-like compounds (isopropyl cloprostenate is the most common), which are not approved drugs but act via similar mechanisms to bimatoprost. These unregulated compounds carry similar side effect risks — including iris pigmentation and periorbital darkening — without the safety data or prescriber oversight that comes with a regulated prescription.

My advice to patients: if you are motivated enough to use an OTC lash serum consistently for months, you are a candidate for the prescription that actually has clinical trial evidence. The cost difference between generic bimatoprost and a high-end OTC serum is often smaller than people expect.

Biotin and Other Supplements

Biotin deficiency does cause hair loss and brittle nails. However, biotin deficiency is rare, and supplementation in people who are not deficient has not been shown to promote hair or lash growth in well-designed clinical trials. The supplement industry has effectively marketed biotin as a universal hair growth solution, but the evidence does not support this for people with normal biotin levels.

Cost, Insurance, and Telehealth Prescribing

What Bimatoprost Costs

Brand-name Latisse (3 mL, approximately a one-month supply) retails for approximately $135–$150 without insurance. A 5 mL bottle (about a two-month supply) runs $165–$212 retail. Generic bimatoprost 0.03% is clinically equivalent and substantially cheaper — as low as $30–$60 with pharmacy discount coupons for a one-month supply.^[9]

Insurance coverage is inconsistent. Bimatoprost for cosmetic eyelash growth is generally not covered by health insurance plans. Allergan (maker of Latisse) has offered a patient savings program for brand-name purchases. Pharmacy discount programs (GoodRx, etc.) can significantly reduce cost for generic versions.

Telehealth Prescribing: Who Is a Good Candidate

Bimatoprost for eyelash hypotrichosis is well-suited to telehealth. The diagnosis is typically straightforward — a patient who wants longer, fuller lashes and does not have adequate lashes by their own assessment. A physician reviewing your history via a telemedicine visit can determine whether you are an appropriate candidate, identify contraindications, and issue the prescription without an in-person visit.

The telehealth consultation for this medication generally covers:

• Medical history review (current eye conditions, existing prostaglandin glaucoma medications, history of uveitis)
• Medication review (identifying drug interactions or contraindications)
• Discussion of side effects and application technique
• Prescription issuance (brand or generic) sent directly to a pharmacy of your choice

Patients who are not good candidates for telehealth prescribing of bimatoprost include those with active eye disease, those already using prostaglandin glaucoma drops (who should coordinate with their ophthalmologist), pregnant patients, and those with a history of uveitis. Most patients with simple, idiopathic eyelash hypotrichosis — meaning thin or sparse lashes with no underlying medical cause — are straightforward telehealth candidates.

Who Gets the Best Results

Bimatoprost works by stimulating follicles that are capable of growing hair. This means the treatment is most effective when the underlying follicles are intact and functional.

Ideal Candidates

• Idiopathic hypotrichosis: Patients who have naturally thin, sparse, or light lashes with no underlying medical cause. This is the primary population studied in the FDA approval trials.
• Post-chemotherapy lash loss: Bimatoprost is studied and effective in patients whose lashes thinned or fell out after chemotherapy. Full follicle recovery may take longer than in idiopathic patients.
• Age-related thinning: Many patients notice their lashes become shorter and less prominent with aging. This is a common and appropriate indication.
• Patients with realistic expectations: Bimatoprost improves what you have — it does not give you an entirely new set of lashes. Patients who understand the 16-week timeline and the maintenance requirement tend to have the best outcomes.

Patients Who May Have Limited Response

• Alopecia areata affecting the lashes: This autoimmune condition destroys hair follicles. Bimatoprost has shown limited benefit in patients with alopecia areata, particularly those with extensive or total lash loss from this cause.
• Scarring from burns or trauma: If follicles are physically destroyed by scar tissue, they cannot respond to bimatoprost.
• Thyroid disease (untreated): Both hypothyroidism and hyperthyroidism cause lash loss. Treating the underlying thyroid condition is the priority; bimatoprost may be a useful adjunct once thyroid levels are controlled.

Frequently Asked Questions